GANXNasdaqPharmaceutical PreparationsUS GAAP · USD

Gain Therapeutics, Inc.

Gain Therapeutics, Inc. is a U.S.-based early-stage biotechnology company developing next-generation brain-penetrant allosteric small molecules through its Magellan™ computational platform. Its lead clinical candidate, GT-02287, is being advanced for Parkinson’s disease and other neurodegenerative disorders, while the company also pursues discovery, preclinical work, and partnering opportunities around its platform technology.

Kysy yhtiöstä
Liikevoitto (EBIT)−18,7milj. USD
+8,1 %v/v
Nettotulos−20,2milj. USD
+1,2 %v/v

Tilikausi 2025 · muutos edellisvuodesta

Kehitys 2020–2025

−25−20−15−10−505milj. USD2020: 0,03 milj. USD2020: EBIT −3,5 milj. USD20202021: 0,16 milj. USD2021: EBIT −14 milj. USD20212022: 0,14 milj. USD2022: EBIT −18 milj. USD20222023: 0,06 milj. USD2023: EBIT −22 milj. USD20232024: 0,06 milj. USD2024: EBIT −20 milj. USD20242025: EBIT −19 milj. USD2025−19
LiikevaihtoLiikevoitto (EBIT)

Liiketoiminta

Osuus liikevaihdosta
Clinical-stage drug candidate0 %

Lead therapeutic program being advanced through clinical development for neurodegenerative disease.

Preclinical discovery pipeline0 %

Earlier-stage small-molecule programs generated from the company’s discovery efforts.

Computational discovery platform0 %

Magellan™ identifies novel allosteric binding sites and potential drug candidates.

Partnering and licensing100 %

Collaborations and licensing arrangements that monetize platform technology and know-how.

Asiakkaat

The company’s direct counterparties are pharmaceutical and biotechnology partners that may license or co-develop programs built on the Magellan™ platform. Its eventual end customers, if products are approved, would be patients and healthcare providers in neurology and other high-unmet-need therapeutic areas. At this stage, the business is funded primarily through capital markets and potential collaboration income rather than product sales.

Pharmaceutical and biotech partners

Buy access to platform-enabled discovery, licensing, or co-development rights to accelerate pipeline creation.

Clinical development stakeholders

Regulators, investigators, and trial sites that support advancement of GT-02287 and future candidates.

Future patients and prescribers

Would use approved therapies for Parkinson’s disease and other neurodegenerative conditions.

Strategia

The company’s strategy is to advance GT-02287 and other Magellan™-derived programs through preclinical and clinical development while preserving liquidity. It also seeks collaboration, licensing, and strategic alliance opportunities to fund development and potentially reduce the capital burden of building a full commercial organization. Because it remains pre-revenue, financing discipline and partnering are central to execution.

Advance clinical-stage lead programLyhyt aikaväli

Clinical progress is the main source of value creation and partnering leverage.

Secure non-dilutive or strategic fundingLyhyt aikaväli

The company has no product revenue and needs capital to fund development.

Broaden platform applicationsKeskipitkä aikaväli

A wider target set can increase the probability of partnering and future pipeline value.

Maantiede

Gain Therapeutics is headquartered in the United States and operates as a U.S.-listed development-stage biotech. Its supply chain is international: the company states that materials for product candidates are currently manufactured in China, creating exposure to trade policy and cross-border sourcing risk. Commercial geography is still limited because it has no approved products or product sales.

Riskit

Gain Therapeutics faces the classic risks of an early-stage biotech: clinical failure, regulatory delay, and the need for repeated financing before any product revenue is possible. It also has meaningful supply-chain and geopolitical exposure because key materials are currently manufactured in China, while tariffs or trade restrictions could raise costs and slow development. As a pre-commercial company, its valuation is highly sensitive to trial outcomes, partnering success, and access to capital.

Järjestetty vakavuuden mukaan
MatalaKohtalainenKorkeaMatalaKohtalainenKorkeaVaikutus →Todennäköisyys →Financing shortfall1Regulatory delay or non-approval3China sourcing and tariff exposure4
Vaikutus on riskin vakavuus ja todennäköisyys sen toteutumisen todennäköisyys lähivuosina, molemmat arvioitu yhtiön raporttien perusteella. Numerot vastaavat listaa.
  1. Financing shortfallVaikutus: KriittinenTodennäköisyys: Matala

    The company expects continued losses and negative operating cash flow.

    KohdistuuR&DTrialsGeneral corporate operations
  2. Clinical development failureVaikutus: Kriittinen

    Lead programs may not demonstrate sufficient safety or efficacy to advance.

    Kohdistuu: GT-02287 and future pipeline candidates

  3. Regulatory delay or non-approvalVaikutus: KorkeaTodennäköisyys: Korkea

    FDA, EMA, or other agencies can slow or block development and commercialization.

    Kohdistuu: Clinical-stage product candidates

  4. China sourcing and tariff exposureVaikutus: KorkeaTodennäköisyys: Kohtalainen

    APIs and other materials are currently manufactured in China, increasing cost and supply risk.

    Kohdistuu: Clinical supply chain and future manufacturing

Kirjanpito

Harkinnanvaraiset erät
Research and development expense accruals

Clinical and discovery costs are estimated before invoices are fully settled.

Vaikutus: Can shift quarterly operating loss and liabilities

Stock-based compensation

A meaningful non-cash cost for a small public biotech with limited revenue.

Vaikutus: Affects operating expenses and comparability across periods

Research grant recognition

Grant income, when present, requires judgment on eligibility and timing.

Vaikutus: Can reduce net loss or offset R&D expense

Collaboration and licensing accounting

Future partner deals may require allocation of consideration and timing judgments.

Vaikutus: Could materially affect revenue timing if deals are signed

Samankaltaisia listattuja yhtiöitä

Julkisesti listattuja yhtiöitä, joilla on samankaltainen liiketoiminta.

Voyager Therapeutics, Inc.

VYGR · Biological Products, (No Diagnostic Substances)

Serina Therapeutics, Inc.

SER · Pharmaceutical Preparations

Marker Therapeutics, Inc.

MRKR · Pharmaceutical Preparations

MapLight Therapeutics, Inc.

MPLT · Pharmaceutical Preparations

GT Biopharma, Inc.

GTBP · Pharmaceutical Preparations

Neurogene Inc.

NGNE · Pharmaceutical Preparations

Päivitetty: 24.9.2026